Skip to main content
Canna~Fangled Abstracts

The role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer’s disease

By December 21, 2021December 30th, 2021No Comments
Review
. 2021 Dec 21.

doi: 10.1002/cbf.3680.

Online ahead of print.
Smita Jain 1, Akansha Bisht 1, Kanika Verma 1, Swarnima Negi 1, Sarvesh Paliwal 1, Swapnil Sharma 1
Affiliations 

Abstract

Fatty acid amide hydrolase (FAAH) is a prominent enzyme of the endocannabinoid system that degrades endogenous cannabinoid anandamide and oleamide. These lipid amides are involved in reducing neuroinflammation, pain and regulation of other neurological-related activities including feeding behaviours, sleep patterns, body temperature, memory processes and locomotory activity. Many of these activities are affected in most neurological disorders. Increased levels of brain FAAH expressions are speculated to correlate with decreased levels of lipid amides and increased AD-related symptoms. Thus, inhibition of FAAH shows promising potential in amelioration of symptoms associated with Alzheimer’s disease (AD). The review aims at establishing the detrimental role of increased FAAH expression in AD and highlights the translational potential and therapeutic application of FAAH inhibitors in AD.

 

Keywords: Alzheimer’s disease, cognition, fatty acid amide hydrolase, neuroinflammation, synaptic plasticity

References

REFERENCES

    1. Egertova M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc R Soc B Biol Sci. 1998;265(1410):2081-2085. doi:10.1098/rspb.1998.0543
    1. Braak H, Del Tredici K. The pathological process underlying Alzheimer’s disease in individuals under thirty. Acta Neuropathol. 2011;121(2):171-181. doi:10.1007/s00401-010-0789-4
    1. Rampa A, Bartolini M, Bisi A, et al. The first dual ChE/FAAH inhibitors: new perspectives for Alzheimer’s disease? ACS Med Chem Lett. 2012;3(3):182-186. doi:10.1021/ml200313p
    1. Hillard CJ. The endocannabinoid signaling system in the CNS: a primer. Int Rev Neurobiol. 2015;125:1-47. doi:10.1016/bs.irn.2015.10.001
    1. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20(2):441-458. doi:10.1111/j.1460-9568.2004.03428.x

Publication types

LinkOut – more resources

  • Full Text Sources

Leave a Reply